Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer

被引：1
|
作者：
Bolla, M. [1 ]
Fourneret, P. [1 ]
Descotes, J. -L. [2 ]
机构：
[1] CHU, Clin Univ Cancerol Radiotherapie, F-63011 Grenoble, France
[2] CHU, Clin Univ Urol, F-63011 Grenoble, France
来源：
BULLETIN DU CANCER | 2008年 / 95卷 / 12期
关键词：
high-risk prostate cancer; combination of external irradiation and androgen suppression;
D O I：
10.1684/bdc.2008.0755
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Treatment of high-risk prostate cancer-localized or locally advanced-is based on the combination of external irradiation and hormonal treatment by LHRH analogue (aLHRH) according to the results of phases III randomized trials RTOG and/or EORTC trials. These trials show a significant improvement of overall or specific survival. Localized prostate cancer require 6-month complete androgen blockade, while locally advanced prostate cancer need a long-term hormonal treatment for a duration ranging from 2,5 to 3 years. Some trials, which have a long follow-up show that the risk of cardiovascular death is not significantly increased by hormonal treatment.
引用
收藏
页码：1213 / 1218
页数：6
相关论文
共 50 条
  • [41] High-risk prostate cancer: treat the prostate
    Cooperberg, Matthew R.
    LANCET, 2011, 378 (9809): : 2056 - 2057
  • [42] Radical Prostatectomy or Radiotherapy in High-Risk Prostate Cancer: A Systematic Review and Metaanalysis
    Petrelli, Fausto
    Vavassori, Ivano
    Coinu, Andrea
    Borgonovo, Karen
    Sarti, Enrico
    Barni, Sandro
    CLINICAL GENITOURINARY CANCER, 2014, 12 (04) : 215 - 224
  • [43] RADIOTHERAPY AND ANDROGEN ABLATION FOR CLINICALLY LOCALIZED HIGH-RISK PROSTATE-CANCER
    POLLACK, A
    ZAGARS, GK
    KOPPLIN, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (01): : 13 - 20
  • [44] The Largest Transcriptomic Resource for Radiotherapy-treated High-risk Prostate Cancer
    Thiruthaneeswaran, N.
    Bibby, B.
    Pereira, R. R.
    Bristow, R. G.
    Choudhury, A.
    West, C. M. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S25 - S25
  • [45] Early. Salvage vs Adjuvant Radiotherapy for High-Risk Prostate Cancer
    Tendulkar, Rahul
    Wu, Wayland J.
    Potters, Louis
    ONCOLOGY-NEW YORK, 2017, 31 (10): : 750 - 754
  • [46] DOSIMETRIC COMPARISON AND TOXICITY ANALYSIS OF STEREOTACTIC RADIOTHERAPY FOR HIGH-RISK PROSTATE CANCER
    Callan, Laura
    Bauman, Glenn
    Chen, Jeff
    Lock, Michael
    Sexton, Tracy
    D'Souza, David
    Rodrigues, George
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S17 - S18
  • [47] New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer
    Tharmalingam, Hannah
    Choudhury, Ananya
    Van Herk, Marcel
    McWilliam, Alan
    Hoskin, Peter J.
    NATURE REVIEWS UROLOGY, 2019, 16 (09) : 523 - 538
  • [48] Estimation of secondary cancer risk after radiotherapy in high-risk prostate cancer patients with pelvic irradiation
    Haciislamoglu, Emel
    Gungor, Gorkem
    Aydin, Gokhan
    Canyilmaz, Emine
    Guler, Ozan Cem
    Zengin, Ahmet Yasar
    Yenice, Kamil Mehmet
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2020, 21 (09): : 82 - 89
  • [49] Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer
    Chun, Seok-Joo
    Kim, Jin Ho
    Ku, Ja Hyeon
    Kwak, Cheol
    Lee, Eun Sik
    Kim, Suzy
    RADIATION ONCOLOGY JOURNAL, 2021, 39 (03): : 231 - 238
  • [50] ⟪ Augmented radiotherapy ⟫ in the management of high-risk prostate cancer (PCa): A systematic review
    Le Guevelou, Jennifer
    Murthy, Vedang
    Zilli, Thomas
    Nicosia, Luca
    Bossi, Alberto
    Bokhorst, Leonard P.
    Barret, Eric
    Ouzaid, Idir
    Nguyen, Paul L.
    Ferrario, Federica
    Chargari, Cyrus
    Arcangeli, Stefano
    Magne, Nicolas
    Sargos, Paul
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 207
12345